A major development in the science of cancer therapy.
Genus Oncology is advancing first-in-class agents from the laboratory as promising drug candidates for the clinic.
Most tumor cells express high levels of the MUC1 protein. Genus has developed a new technology platform to target overexpression of MUC1 and reverse a wide range of otherwise intractable cancers.
The number of cancers that have elevated levels of MUC1 represents a significant opportunity. The MUC1 protein is over expressed in 80–90% of all solid tumors and many hematologic cancers, which represents a very large market for a novel drug. Genus is developing targeted therapies that can potentially treat a wide range of carcinomas, including breast, lung, prostate, colon, ovarian, and pancreatic cancers, which affect millions of patients every year. Developing peptide, antibody, and small molecule drugs to treat cancer, Genus is directly targeting specific sites on the widely implicated Mucin 1 (MUC1) protein to block the protein interactions that transform normal cells into tumor cells. Importantly, Genus also has developed specific biomarker assays that identify patients most likely to respond to therapy. Our technology is unique and our success to date in models of intractable cancers is unprecedented.